ArriVent BioPharma, Inc.

For the period ended Sep 30, 2026. Filed Nov 9, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2026 · Filed Nov 9, 2026

AVBP$13.49-4.7%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Statements of Operations and Comprehensive Loss

CONDENSED STATEMENTS OF OPERATIONS

** AND COMPREHENSIVE LOSS**

(in thousands, except share and per share data)


· · Three Months Ended · · · Nine Months Ended ·
· · September 30, · · September 30, ·
· · 2026 · · 2025 · · 2026 · · 2025 ·

Collaboration revenue	$5,000	$—	$5,000	$—

Operating expenses:
Research and development	38,897	32,167	118,853	121,176
General and administrative	9,479	6,149	28,324	17,535
Total operating expenses	48,376	38,316	147,177	138,711
Operating loss	(43,376)	(38,316)	(142,177)	(138,711)
Interest and investment income	3,063	3,338	8,651	7,947
Net loss	(40,313)	(34,978)	(133,526)	(130,764)
Unrealized gain (loss) on investments	(199)	226	(480)	419
Total other comprehensive gain (loss)	(199)	226	(480)	419
Total comprehensive loss	$(40,512)	$(34,752)	$(134,006)	$(130,345)

Share information:
Net loss per share attributable to common stockholders, basic and diluted	$(0.81)	$(0.83)	$(2.82)	$(3.54)
Weighted-average shares of common stock outstanding, basic and diluted	49,526,356	41,912,905	47,425,424	36,968,978

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.